KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Depreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - OtherShares OutstandingShares Outstanding
Ratios

TherapeuticsMD (TXMD) Cost of Revenue (2016 - 2023)

TherapeuticsMD filings provide 13 years of Cost of Revenue readings, the most recent being $106000.0 for Q3 2023.

  • On a quarterly basis, Cost of Revenue fell 70.06% to $106000.0 in Q3 2023 year-over-year; TTM through Dec 2023 was $106000.0, a 92.41% decrease, with the full-year FY2022 number at $1.4 million, changed 0.36% from a year prior.
  • Cost of Revenue hit $106000.0 in Q3 2023 for TherapeuticsMD, down from $354000.0 in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $30.0 million in Q3 2021 to a low of -$84.8 million in Q4 2021.
  • Median Cost of Revenue over the past 5 years was $2.1 million (2019), compared with a mean of $1.1 million.
  • The widest YoY moves for Cost of Revenue: up 815.07% in 2021, down 426.17% in 2021.
  • TherapeuticsMD's Cost of Revenue stood at $2.9 million in 2019, then surged by 802.95% to $26.0 million in 2020, then tumbled by 426.17% to -$84.8 million in 2021, then surged by 100.42% to $354000.0 in 2022, then crashed by 70.06% to $106000.0 in 2023.
  • The last three reported values for Cost of Revenue were $106000.0 (Q3 2023), $354000.0 (Q3 2022), and $348000.0 (Q2 2022) per Business Quant data.